Evidence map›Paper›PMID 26483873›Full record

ReviewWorld journal of gastrointestinal oncology2015

Fecal DNA testing for colorectal cancer screening: Molecular targets and perspectives.

Amaninder Dhaliwal, Panagiotis J Vlachostergios, Katerina G Oikonomou, Yitzchak Moshenyat

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastrointestinal oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. From Detection to Delay: Real-World Gaps in Post-CologuardJournal of gastrointestinal cancer · 2025
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. World journal of gastroenterology · 2020
    Article
  12. Article
  13. Review
  14. Review
  15. Detection ofWorld journal of gastroenterology · 2017
    Article
  16. Article
  17. Current and future biomarkers in colorectal cancer.Annals of gastroenterology · 2017
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Amaninder DhaliwalAmaninder Dhaliwal, Panagiotis J Vlachostergios, Katerina G Oikonomou, Department of Medicine, NYU Lutheran Medical Center, Brooklyn, NY 11220, United States.
Panagiotis J VlachostergiosAmaninder Dhaliwal, Panagiotis J Vlachostergios, Katerina G Oikonomou, Department of Medicine, NYU Lutheran Medical Center, Brooklyn, NY 11220, United States.
Katerina G OikonomouAmaninder Dhaliwal, Panagiotis J Vlachostergios, Katerina G Oikonomou, Department of Medicine, NYU Lutheran Medical Center, Brooklyn, NY 11220, United States.
Yitzchak MoshenyatAmaninder Dhaliwal, Panagiotis J Vlachostergios, Katerina G Oikonomou, Department of Medicine, NYU Lutheran Medical Center, Brooklyn, NY 11220, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The early detection of colorectal cancer with effective screening is essential for reduction of cancer-specific mortality. The addition of fecal DNA testing in the armamentarium of screening methods already in clinical use launches a new era in the noninvasive part of colorectal cancer screening and emanates from a large number of previous and ongoing clinical investigations and technological advancements. In this review, we discuss the molecular rational and most important genetic alterations hallmarking the early colorectal carcinogenesis process. Also, representative DNA targets-markers and key aspects of their testing at the clinical level in comparison or/and association with other screening methods are described. Finally, a critical view of the strengths and limitations of fecal DNA tests is provided, along with anticipated barriers and suggestions for further exploitation of their use.

Indexed as

AdenomaCologuard®Colorectal cancerFecal DNAScreening

Identifiers

PMID26483873
PMCPMC4606173

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.